Northwestern Mutual Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.5K | Buy |
254
+52
| +26% | +$6.9K | ﹤0.01% | 2596 |
|
|
2025
Q4 | $28.6K | Sell |
202
-5
| -2% | -$724 | ﹤0.01% | 2604 |
|
|
2025
Q3 | $29.1K | Sell |
207
-418
| -67% | -$56.6K | ﹤0.01% | 2538 |
|
|
2025
Q2 | $78.6K | Sell |
625
-368
| -37% | -$42.2K | ﹤0.01% | 2086 |
|
|
2025
Q1 | $110K | Sell |
993
-260
| -21% | -$32.9K | ﹤0.01% | 1898 |
|
|
2024
Q4 | $171K | Buy |
1,253
+116
| +10% | +$14.3K | ﹤0.01% | 1719 |
|
|
2024
Q3 | $131K | Buy |
1,137
+380
| +50% | +$52.1K | ﹤0.01% | 1787 |
|
|
2024
Q2 | $104K | Buy |
757
+50
| +7% | +$6.86K | ﹤0.01% | 1816 |
|
|
2024
Q1 | $97.5K | Buy |
707
+6
| +0.9% | +$819 | ﹤0.01% | 1817 |
|
|
2023
Q4 | $92.4K | Buy |
701
+367
| +110% | +$42.2K | ﹤0.01% | 1813 |
|
|
2023
Q3 | $37.6K | Sell |
334
-52
| -13% | -$5.48K | ﹤0.01% | 2080 |
|
|
2023
Q2 | $36.4K | Sell |
386
-39
| -9% | -$3.81K | ﹤0.01% | 2103 |
|
|
2023
Q1 | $43K | Sell |
425
-145
| -25% | -$15.1K | ﹤0.01% | 1993 |
|
|
2022
Q4 | $68.1K | Sell |
570
-2,383
| -81% | -$279K | ﹤0.01% | 1808 |
|
|
2022
Q3 | $314K | Sell |
2,953
-45
| -2% | -$4.57K | ﹤0.01% | 1236 |
|
|
2022
Q2 | $292K | Buy |
2,998
+64
| +2% | +$5.91K | ﹤0.01% | 1267 |
|
|
2022
Q1 | $275K | Sell |
2,934
-94
| -3% | -$7.97K | ﹤0.01% | 1319 |
|
|
2021
Q4 | $258K | Buy |
3,028
+98
| +3% | +$9.02K | ﹤0.01% | 1328 |
|
|
2021
Q3 | $281K | Buy |
2,930
+50
| +2% | +$4.72K | ﹤0.01% | 1218 |
|
|
2021
Q2 | $281K | Sell |
2,880
-1,222
| -30% | -$117K | ﹤0.01% | 1191 |
|
|
2021
Q1 | $399K | Buy |
4,102
+2,913
| +245% | +$305K | ﹤0.01% | 998 |
|
|
2020
Q4 | $114K | Sell |
1,189
-2,320
| -66% | -$224K | ﹤0.01% | 1358 |
|
|
2020
Q3 | $337K | Buy |
3,509
+1,813
| +107% | +$210K | ﹤0.01% | 861 |
|
|
2020
Q2 | $207K | Buy |
1,696
+1,617
| +2,047% | +$179K | ﹤0.01% | 958 |
|
|
2020
Q1 | $7K | Buy |
79
+17
| +27% | +$1.66K | ﹤0.01% | 1991 |
|
|
2019
Q4 | $7K | Buy |
62
+2
| +3% | +$209 | ﹤0.01% | 1998 |
|
|
2019
Q3 | $5K | Sell |
60
-26
| -30% | -$2.43K | ﹤0.01% | 2101 |
|
|
2019
Q2 | $7K | Hold |
86
| – | – | ﹤0.01% | 2050 |
|
|
2019
Q1 | $7K | Sell |
86
-174
| -67% | -$14.5K | ﹤0.01% | 2052 |
|
|
2018
Q4 | $19K | Buy |
260
+164
| +171% | +$15.7K | ﹤0.01% | 1610 |
|
|
2018
Q3 | $12K | Hold |
96
| – | – | ﹤0.01% | 1873 |
|
|
2018
Q2 | $9K | Sell |
96
-15
| -14% | -$1.34K | ﹤0.01% | 1864 |
|
|
2018
Q1 | $9K | Buy |
111
+15
| +16% | +$1.27K | ﹤0.01% | 1784 |
|
|
2017
Q4 | $7K | Hold |
96
| – | – | ﹤0.01% | 1858 |
|
|
2017
Q3 | $6K | Hold |
96
| – | – | ﹤0.01% | 1783 |
|
|
2017
Q2 | $4K | Buy |
+96
| New | +$4.66K | ﹤0.01% | 1782 |
|
Other funds holding NBIX
VPM
VCM
Northwestern Mutual Wealth Management's NBIX Position: Q1 2026 in Review
Northwestern Mutual Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 26% in Q1 2026, buying an estimated $6.9K and bringing the position to 254 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2596.
Northwestern Mutual Wealth Management first reported a position in NBIX in Q2 2017 and has held it in 36 quarters since. The position peaked at $399K in Q1 2021. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Northwestern Mutual Wealth Management held 254 shares of Neurocrine Biosciences worth $33.5K as of Q1 2026.
- Northwestern Mutual Wealth Management bought 52 Neurocrine Biosciences shares in Q1 2026, an estimated $6.9K.
- Neurocrine Biosciences made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q1 2026, its #2596 holding.
- Northwestern Mutual Wealth Management first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 36 quarters since.
- Northwestern Mutual Wealth Management's Neurocrine Biosciences position peaked at $399K in Q1 2021.
- 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.